Discover
LRMR
Larimar Therapeutics, Inc.
3.21
2 x 2.32
2 x 3.89
bid
ask
+
0.16
5.25%
2 @ 04:00 PM
3.22 +0.01 (0.31%)
| Ytd | -15.75% | |
| 1y | 3.22% |
3.01
day range
3.25
2.71
52 week range
6.42
| Open | 3.05 | Prev Close | 3.05 | Low | 3.01 | High | 3.25 | Mkt Cap | 333.46M |
| Vol | 2.61M | Avg Vol | 2.06M | EPS | -2.12 | P/E | N/A | Forward P/E | -2.57 |
| Beta | 0.71 | Short Ratio | 5.19 | Inst. Own | 106.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 3.72 | 200-d Avg | 3.97 | 1yr Est | 20.41 |
| Income Statement | |||
| Operating Expenses | 31.12M | ||
| Research and Development Expense | 25.03M | ||
| Selling, General and Administrative Expense | 6.09M | ||
| Operating Income | -31.12M | ||
| Net Income | -29.61M | ||
| Net Income Common Stock | -29.61M | ||
| Net Income Common Stock (USD) | -29.61M | ||
| Consolidated Income | -29.61M | ||
| Earnings per Basic Share | -0.31 | ||
| Earnings per Basic Share (USD) | -0.31 | ||
| Earnings per Diluted Share | -0.31 | ||
| Earning Before Interest & Taxes (EBIT) | -29.61M | ||
| Earning Before Interest & Taxes (USD) | -29.61M | ||
| Weighted Average Shares | 89.81M | ||
| Weighted Average Shares Diluted | 89.81M | ||
| Balance Sheet | |||
| Cash and Equivalents | 178.52M | ||
| Cash and Equivalents (USD) | 178.52M | ||
| Investments | 22.47M | ||
| Investments Current | 22.47M | ||
| Current Assets | 204.98M | ||
| Property, Plant & Equipment Net | 2.42M | ||
| Total Assets | 208.51M | ||
| Debt Current | 1.06M | ||
| Total Debt | 3.78M | ||
| Current Liabilities | 47.76M | ||
| Debt Non-Current | 2.72M | ||
| Total Liabilities | 50.48M | ||
| Accumulated Retained Earnings (Deficit) | -464.44M | ||
| Accumulated Other Comprehensive Income | 6.00K | ||
| Shareholders Equity | 158.03M | ||
| Shareholders Equity (USD) | 158.03M | ||
| Assets Non-Current | 3.53M | ||
| Total Debt (USD) | 3.78M | ||
| Liabilities Non-Current | 2.72M | ||
| Trade and Non-Trade Payables | 8.58M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | -21.00K | ||
| Net Cash Flow from Financing | 108.12M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 92.50M | ||
| Issuance (Purchase) of Equity Shares | 108.12M | ||
| Net Cash Flow from Investing | 29.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 29.00M | ||
| Net Cash Flow from Operations | -44.61M | ||
| Share Based Compensation | 1.98M | ||